Differential gene expression analysis of MYCN-amplified neuroblastoma cells after THZ1 and TKI combination therapy.. Differential gene expression analysis of MYCN-amplified neuroblastoma cells after THZ1 and TKI combination therapy.

The CDK7 inhibitor THZ1 has been shown to suppress MYCN gene transcription but not cause significant cell death as a single agent. The tyrosine kinase inhibitors (TKIs) ponatinib and lapatinib were found to exert synergistic anti-cancer effects in combination with the CDK7 inhibitor THZ1, on MYCN amplified neuroblastoma cell lines. Overall design: We performed Affymetrix Human Gene 2.0 ST microarray experiments in BE2C neuroblastoma cells after 6hrs treatment with either vehicle control, 32nM THZ1, 250nM ponatinib, 1000nM lapatinib, THZ1 + ponatinib or THZ1 + lapatinib. Differential expression analysis (drug treatment - vehicle control) was analysed for each drug treatment.